Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/26/14  and contains information from public web pages and contributions from the ZoomInfo community.

Michael Wade Ph.D.

Wrong Michael Wade Ph.D.?

Executive Vice President, Global ...

Local Address: Research Triangle Park, North Carolina, United States
United Therapeutics Corporation
1040 Spring St
Silver Spring, Maryland 20910
United States

Company Description: United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the medical needs of patients...   more
Background

Employment History

Education

  • Ph.D.
Web References
DisabilityTimes.com: United Therapeutics Corporation Completes Enrollment In Phase III Intermittent Claudication Study
www.disabilitytimes.com, 20 Feb 2001 [cached]
``Our trial was designed to confirm the very positive results of BERCI2 , '' said Michael Wade , Ph.D. , Associate Director of Research and Development for United Therapeutics. ``Successful completion of this study will be an important milestone in our goal of filling a large unmet medical need for safe , effective treatments for intermittent claudication , which affects millions of people.''.
Beraprost is the first and only orally available analog of prostacyclin , a potent naturally occurring vasodilator and inhibitor of platelet aggregation.Beraprost was exclusively licensed to United Therapeutics by Toray Industries , Inc. of Japan for the North American market.In Japan , beraprost has been proven in clinical studies to be safe and effective for the treatment of peripheral vascular disease.The drug has been approved in Japan since 1994 and Toray's annual sales of beraprost there exceed $250 million.
A Japanese study presented at the 1998 American Heart Association meeting suggests that beraprost may also improve survival in patients with pulmonary hypertension.
Today's News
www.prnewswire.com, 13 Nov 2002 [cached]
United Therapeutics Announces Promotion of Dean Bunce to Vice President, Regulatory Affairs and Michael Wade to Vice President, Development and Medical Affairs
...
RESEARCH TRIANGLE PARK, N.C., Nov. 13 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today the promotions of Dean Bunce to Vice President of Regulatory Affairs and Michael Wade, Ph.D. to Vice President of Development and Medical Affairs.
...
Dr. Wade joined United Therapeutics in 1997 and has nearly ten years of drug development experience; Dr. Wade has led project teams in all phases investigating multiple therapeutic areas.
...
Likewise, Dr. Wade has been one of the key individuals responsible for the clinical development of Remodulin since its infancy, and is currently responsible for all post- approval studies of Remodulin, including the Phase IV Flolan transition study and the critical limb ischemia development effort."
...
Dr. Wade will continue to be responsible for all post-marketing studies of Remodulin(R) (treprostinil sodium) Injection, United Therapeutics' therapy for the treatment of pulmonary arterial hypertension, and for progressing early stage compounds into and through clinical development.United Therapeutics is a biotechnology company focused on combating cardiovascular, infectious and oncological diseases with unique therapeutic products.
Click here
Research Triangle Park :: RTP In the News
www.rtp.org, 27 Jan 2004 [cached]
"We are pleased that Remodulin meets the criteria for bioequivalence," said Michael Wade, vice president of development and medical affairs at United Therapeutics.
Drugmax.com * The Premier Business-To-Business E-Commerce Trade Exchange for Professionals in the Pharmaceutical, Over-The-Counter, Health & Beauty and Private Label Industries/NewsAlert - Story
www.drugmax.newsalert.com, 20 Feb 2001 [cached]
Our trial was designed to confirm the very positive results of BERCI2, said Michael Wade, Ph.D., Associate Director of Research and Development for United Therapeutics.Successful completion of this study will be an important milestone in our goal of filling a large unmet medical need for safe, effective treatments for intermittent claudication, which affects millions of people..
Beraprost is the first and only orally available analog of prostacyclin, a potent naturally occurring vasodilator and inhibitor of platelet aggregation.Beraprost was exclusively licensed to United Therapeutics by Toray Industries, Inc. of Japan for the North American market.In Japan, beraprost has been proven in clinical studies to be safe and effective for the treatment of peripheral vascular disease.The drug has been approved in Japan since 1994 and Toray's annual sales of beraprost there exceed $ 250 million.
Other People with the name "Wade":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304